INTRODUCTION: CASE REPORT:



Similar documents
SEMESTER VI 3 RD YEAR PATHOLOGY KIDNEY TUMORS

Medullary Renal Cell Carcinoma Case Report

RENAL CANCER PATHOLOGY WHAT REALLY MATTERS? STEWART FLEMING UNIVERSITY OF DUNDEE

Something Old, Something New.

A912: Kidney, Renal cell carcinoma

Translocation Renal Cell Carcinomas

Multiple Primary and Histology Site Specific Coding Rules KIDNEY. FLORIDA CANCER DATA SYSTEM MPH Kidney Site Specific Coding Rules

CASE OF THE MONTH AUGUST-2015 DR. GURUDUTT GUPTA HEAD HISTOPATHOLOGY

KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA

Four Important Facts about Kidney Cancer

Oncological outcome of surgical treatment in 336 patients with renal cell carcinoma

KIDNEY CARCINOMA ASSOCIATED WITH XP11.2 TRANSLOCATION / TFE3 (ASPL-TFE3) GENE FUSION

Renal Pathology Update. Sundus Hussein MD, FRCPC

Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer

Histologic Subtypes of Renal Cell Carcinoma

NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)

The Lewin Group undertook the following steps to identify the guidelines relevant to the 11 targeted procedures:

UCLH. Transurethral resection of bladder tumour (TURBT) Urology Directorate

Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.

The WHO Classification of Renal Tumors and Common Issues in TNM Staging for Renal Cell Carcinoma

Kidney Cancer OVERVIEW

Treatment for bladder tumours - transurethral resection of a bladder tumour (TURBT)

CONTEMPORARY MANAGEMENT OF RENAL ANGIOMYOLIPOMA

A Very Rare Indication in Urology: Ablation of all the Urinary Organs: About A Case

Guidelines for Management of Renal Cancer

Clinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment

PARANEOPLASTIC SIGNS AND SYMPTOMS OF RENAL CELL CARCINOMA: IMPLICATIONS FOR PROGNOSIS

Kidney Cancer: Survival Report. Urological Cancers SSCRG

Combined Harvard Urologic Oncology Fellowship Program

Case Number: RT (M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor

CHAPTER 2: UNDERSTANDING CANCER

WHAT S WRONG WITH MY GALL BLADDER? GALL BLADDER POLYPS

CT and MRI features of the Pathologic Subtypes of Papillary Renal Cell Carcinoma. Melissa Price, MD Aoife Kilcoyne, MD Mukesh G.

Intraobserver and Interobserver Reproducibility of WHO and Gleason Histologic Grading Systems in Prostatic Adenocarcinomas

The Role of Genetic Testing in the Evaluation of Thyroid Nodules. Thyroid Cancer and FNA. Thyroid Cancer. Pure Follicular Cancers.

Title: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma

Common Cancers & Hereditary Syndromes

Kidney Cancer (Adult) - Renal Cell Carcinoma What is cancer?

Introduction. Case History

Renal Tumors with Eosinophilic Cytoplasm: 2013 Classification. Jesse K. McKenney, MD Associate Head, Surgical Pathology

Frozen Section Diagnosis

Bladder Cancer What is bladder cancer?

Thursday, November 3, 2005

Gladwyn Leiman, MCCCh, FIAC, FRCPath Scott Anderson, MD

Carcinoma papilar renal, cromófobo y otras histologías. Maria José Méndez Vidal Servicio de oncología Medica Hospital Reina Sofía Córdoba

Smoking and misuse of certain pain medicines can affect the risk of developing renal cell cancer.

95% of childhood kidney cancer cases are Wilms tumours. Childhood kidney cancer is extremely rare, with only 90 cases a year in

Prostate Cancer Screening. A Decision Guide for African Americans

TRANSURETHRAL RESECTION OF A BLADDER TUMOUR (TURBT) PATIENT INFORMATION

Transurethral Resection of Bladder Tumour (T.U.R.B.T)

Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma

Case Based Urology Learning Program

Genetics Gender plays a role in kidney cancer, as men are twice as likely as women to develop RCC

Transperitoneal laparoscopic adrenalectomy for metachronous contralateral

VHL and clear cell Renal Cell Carcinoma. Expression profiling reveals cell of origin. Renal Cell Carcinoma (RCC) Title. VHL syndrome hallmark cancer:

Neoplasms of the LUNG and PLEURA

A918: Prostate: adenocarcinoma

These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.

The TV Series. INFORMATION TELEVISION NETWORK

Histopathology and prognosis in renal cancer

Challenges in gastric, appendiceal and rectal NETs Leuven,

GENETICS AND GENOMICS OF THYROID NEOPLASMS MOVING CLOSER TOWARDS PERSONALIZED PATIENT CARE

Metastatic Renal Cell Carcinoma Risk According to Tumor Size

SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR.

Prostate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40.

Carcinoma of the vagina is a relatively uncommon disease, affecting only about 2,000 women in

Male. Female. Death rates from lung cancer in USA

The evolving pathology of solitary fibrous tumours. Luciane Dreher Irion MREH / CMFT / NSOPS

Sonographic Diagnosis of Ureteral Tumors

Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD

There are many different types of cancer and sometimes cancer is diagnosed when in fact you are not suffering from the disease at all.

From Immunotherapy of Cancer to the Discovery of Kidney Cancer Genes

Thyroid Cancer Diagnosis and Management. Jerome Hershman, M.D. Internal Medicine Grand Rounds University of Missouri, Columbia October 21, 2010

Role of histopatological assessment of renal cancer specimen after radical and partial nephrectomy

<1 cm WDT-UMP, FT-UMP. Kakudo K et al, Pathol Int,2009, Endocr J, 2011 and Pathol Int, 2012

Targeted Molecular Therapy for Renal Cell Carcinoma: Impact on Existing Treatment Paradigms

Lung Cancer: More than meets the eye

Urinary Diversion: Ileovesicostomy/Ileal Loop/Colon Loop

Outline. Workup for metastatic breast cancer. Metastatic breast cancer

Transcription:

Balekuduru Chaitanya et SYNCHRONOUS OCCURRENCE OF PAPILLARY RENAL CELL CARCINOMA AND TRANSITIONAL UROTHELIAL CELL CARCINOMA OF URINARY BLADDER a case report S. Rajasekhar Reddy 1, Balekuduru Chaitanya* 2, P. Swarna Latha 1 1. Nizam s Institute of Medical Sciences Hyderabad, Andhra Pradesh, India. 2.Dr. NTR University of Health sciences, Vijayawada, Andhra Pradesh, India. *E-mail: bharadwaj.chaitanya@yahoo.com Abstract: The occurrence of both urothelial carcinoma and renal cell carcinoma is normally high in the elderly population. However simultaneous occurrence i.e synchronicity, of transitional cell carcinoma of urinary bladder and renal cell carcinoma of kidney is uncommon especially combination of papillary renal cell carcinoma & transitional cell carcinoma is very rare. We report a case of an elderly man with synchronous presentation of papillary renal cell carcinoma and transitional cell carcinoma of the urinary bladder. Keywords: Papillary Renal Cell Carcinoma, Transitional Cell Carcinoma, Synchronous Malignancy INTRODUCTION: RCC, the most lethal among urologic malignancies accounts for 2 3 % of all adult malignant neoplasms. [1][2] In men, urothelial carcinoma of the bladder is the fourth most common cancer after prostate, lung, and colorectal cancers, accounting for 6.6% of all cancer cases. [3] Both the malignancies tend to occur in elderly men in the sixth to seventh decades. [4] However simultaneous occurrence is very rare. CASE REPORT: A 69 year old male presented with complaints of 3 episodes of painless haematuria of 3 months duration and a swelling in the left loin of 2 months duration associated with pain. He is a chronic smoker with no significant past history or family history. Per abdomen revealed a palpable mass in the left hypochondrium and lumbar regions. Complete urine examination showed 6-8 RBC/ HPF. Other renal parameters were within normal limits. Ultrasonography showed a well defined heterogenous mass of 8 cm in diameter arising from lower pole of left kidney and an irregular hyperechoeic lesion of 2 cm along left lateral wall of bladder. Contrast enhanced computerised tomography (CECT) abdomen showed a large heterogenous enhancing lesion arising from lower pole of left kidney suggestive of a renal tumor and a small mildly enhancing papillary growth from left lateral wall of bladder ( Figure 1). Transurethral resection of bladder tumor (TURBT) and left radical nephrectomy was done in the same sitting. TUR accompanied by fulgaration of the papillary growth on left lateral wall and three small growths over right lateral wall of urinary bladder was performed along with left radical nephrectomy by transperitoneal approach. Histopathological examination revealed papillary variant of renal cell carcinoma of left kidney (stage T2N0M0) and a low grade transitional cell carcinoma of the bladder without deep muscle invasion. Gross specimen of left nephrectomy and histopathological images of papillary RCC and transitional cell carcinoma of bladder are herewith enclosed as figures 2-6. Patient had an uneventful inpatient course and was advised regular follow-up after discharge. 498

Balekuduru Chaitanya et Fig:1 CECT showing growth in left kidney and in urinary bladder Fig: 2. Gross photograph of left nephrectomy y specimen showing variegated appearance of tumour inn the upper pole. 499

Balekuduruu Chaitanya et Fig: 3. Papillary RCC with macrophages in the core of papillae, H&E, 100x Fig: 4. Cellular anaplasia of lining cells of papillae alongg with macrophage, H& &E,400x 500

Balekuduru Chaitanya et Fig:5. Transitional cell carcinoma, low power view, H& &E,100x Fig: 6. Nuclear atypia & stratification in TCC,Bladder, H&E,400x 501

Balekuduru Chaitanya et DISCUSSION: Though many case reports simultaneous occurrence of clear cell renal cell carcinoma and transitional cell carcinoma of bladder are on record, coexistent papillary renal cell carcinoma with transitional carcinoma of bladder are very rare. [5][6] The most prominent risk factor of both renal cell carcinoma and transitional cell carcinoma is tobacco and this patient was found to be a chronic smoker. In addition germline and somatic mutations of c-met proto-oncogene on human chromosome 7q31-34 are specifically associated with papillary renal carcinoma and also expression of c-met in the papillary urothelial carcinoma of the urinary bladder was positively associated with histologic grade, stage, tumor size and growth pattern and c-met protooncogene has been reported to play a more important role in the progression of bladder cancers. [7][8][9][10] The role of similar risk factors and germline mutations involving the oncogenes and tumor suppressor genes can be of interest for research and provide insights into the pathogenetic mechanisms behind the occurrence of these dual malignancies. The management of such dual malignancies still remains a therapeutic challenge. Prognosis in instances of synchronous malignancies remains poor with the outcome being more influenced by the aggressive primary among the two. REFERENCES: [1]. Renal Tumours, in Campbell s Urology, Steven C. Campbell, Andrew C.Novack,Ronald M.Bukowski, Saunders, Philadelphia, PA, USA, 9th edition,2007. [2]. Pantuck et al., 2001b. Pantuck AJ, Zisman A, Belldegrun AS: The changing natural history of renal cell carcinoma. J Urol 2001; 166:1611-1623. [3]. Jemal et al., 2005. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30. [4]. Lynch and Cohen, 1995. Lynch CF, Cohen MB: Urinary system. Cancer 1995; 75(Suppl):316. [5]. Mazeman I. Tumors of the upper urinary tract, calyces, renal pelvis and ureter. Eur Urol. 1976;2:120. [PubMed] [6]. Huben RP, Mounzer AM, Murphy GP. Tumor grade and stage as prognostic variables in upper tract urothelial tumors. Cancer. 1988;62:2016. [PubMed] [7]. Schmidt L, Duh F-M, Chen F, Kishida T, Glenn G, Choyke P, Scherer S, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casade- vall C, Zamarron A, Bernues M, Richard S, Lips CJM, WaltherMM, Tsui L-C, Geil L, OrcuttML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, NiehansG,Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM and Zbar B. (1997). Nature Genet., 16, 68 ± 73. [8]. Joseph A, Weiss GH, Jin L, et al: Expression of scatter factor in human bladder carcinoma. J Natl Cancer Inst 87:372-377, 1995. [9]. Li B, Kanamaru H, Noriki S, et al: Differential expression of hepatocyte growth factor in papillary and nodular tumors of the bladder. Int J Urol 5:436-440, 1998. [10]. Chow NH, Trink B, Eisenberger C, et al: Tyrosine kinase profile of bladder cancer. J Urol 159:1096, 1998 (abstr) 502